Connor, Clark & Lunn Investment Management Ltd. Novo Cure LTD Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Novo Cure LTD stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 426,263 shares of NVCR stock, worth $11.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
426,263
Previous 366,655
16.26%
Holding current value
$11.2 Million
Previous $6.28 Million
6.08%
% of portfolio
0.04%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding NVCR
# of Institutions
262Shares Held
76.9MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$318 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$310 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$207 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$113 Million0.01% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$79.3 Million12.67% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.75B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...